{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:10:22Z","timestamp":1790939422710,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,2,13]],"date-time":"2006-02-13T00:00:00Z","timestamp":1139788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2006,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anti\u2010angiogenesis is a promising strategy for cancer therapy currently evaluated in clinical trials. The aim of the study was to investigate the effects of an antiangiogenic combination therapy inhibiting \u03b1<jats:sub>v<\/jats:sub>\u2010integrins by a c(yclic)RGD\u2010peptide (EMD270179) and blocking VEGFR\u20102 by SU5416 on tumor angiogenesis and progression <jats:italic>in vivo<\/jats:italic>. Experiments were performed in dorsal skinfold chamber preparations of Syrian golden hamster<jats:italic>s<\/jats:italic> (60 \u00b1 5 g) bearing A\u2010Mel\u20103 tumors. From day 3\u201310 after tumor\u2010cell implantation, animals (<jats:italic>n<\/jats:italic> = 6 per group) were treated by monotherapies using the cRGD\u2010peptide (114 mg\/kg\/day; i.p.), the VEGFR\u20102 antagonist (6 mg\/kg\/day; i.p.) or by the combination of both monotherapies. A control group received only the solvent DMSO. Using intravital microscopy parameters of intratumoral microcirculation were analyzed on day 5, 7 and 10. In separate experiments subcutaneous tumor growth and metastasis formation was evaluated starting therapy on day 0. Functional vessel density was significantly reduced by the combination therapy compared to that by all other groups on day 10. Although intratumoral red blood cell velocity and vessel diameters were less affected, blood flow in vessel segments and the microcirculatory perfusion index were lower after combined therapy compared to controls. In addition, we observed a significantly stronger inhibition of subcutaneous tumor growth and metastasis formation using the combination therapy. These data clearly support the concept of antiangiogenic combination therapy and demonstrate that it may especially be effective when scheduled as an early or prophylactic treatment regimen, thus avoiding angiogenesis\u2010dependent tumor and metastasis initiation or tumor recurrence. \u00a9 2006 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.21838","type":"journal-article","created":{"date-parts":[[2006,2,13]],"date-time":"2006-02-13T22:46:48Z","timestamp":1139870808000},"page":"423-431","source":"Crossref","is-referenced-by-count":30,"title":["Antiangiogenic combination tumor therapy blocking \u03b1<sub>v<\/sub>\u2010integrins and VEGF\u2010receptor\u20102 increases therapeutic effects <i>in vivo<\/i>"],"prefix":"10.1002","volume":"119","author":[{"given":"Sebastian","family":"Strieth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Eichhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Jonczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Berghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Dellian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,4,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc905"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI8829"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601401"},{"key":"e_1_2_6_5_2","first-page":"1931","article-title":"What do oncogenic mutations have to do with angiogenesis\/vascular dependence of tumors?","volume":"62","author":"Rak J","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1369"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104819"},{"key":"e_1_2_6_8_2","first-page":"1957","article-title":"Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction","volume":"9","author":"Wachsberger P","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_2_6_10_2","first-page":"99","article-title":"SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk\u20101\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types","volume":"59","author":"Fong TA","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0404"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0221-3"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.046"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.6.1657"},{"key":"e_1_2_6_15_2","first-page":"4772","article-title":"SU5416 plus interferon\u2010\u03b1 in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition","volume":"9","author":"Lara PNJ","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_16_2","first-page":"8890","article-title":"Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects","volume":"63","author":"Abdollahi A","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7512751"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90007-8"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600141"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2000.15.71"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5241.1500"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.4.882"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600318"},{"key":"e_1_2_6_24_2","first-page":"1898","article-title":"Quantitative analysis of microvascular structure and function in the amelanotic melanoma A\u2010Mel\u20103","volume":"41","author":"Asaishi K","year":"1981","journal-title":"Cancer Res"},{"key":"e_1_2_6_25_2","first-page":"475","article-title":"Microcirculatory blood flow, capillary morphology and local oxygen pressure of the hamster amelanotic melanoma A\u2010Mel\u20103","volume":"68","author":"Endrich B","year":"1982","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1515\/bmte.1997.42.6.168"},{"key":"e_1_2_6_27_2","first-page":"293","article-title":"Computer assisted leukocyte adhesion measurement in intravital microscopy","volume":"8","author":"Zeintl H","year":"1989","journal-title":"Int J Microcirc Clin Exp"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-2862(74)90043-0"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02087.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.5.2002"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000073281"},{"key":"e_1_2_6_32_2","first-page":"2798","article-title":"Results of a phase I dose\u2010escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies","volume":"8","author":"Stopeck A","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_33_2","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug\u2010resistant cancer","volume":"60","author":"Browder T","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_6_34_2","first-page":"221","article-title":"Differences in therapeutic indexes of combination metronomic chemotherapy and an anti\u2010VEGFR\u20102 antibody in multidrug\u2010resistant human breast cancer xenografts","volume":"8","author":"Klement G","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_35_2","first-page":"4848","article-title":"The angiogenesis inhibitor SU5416 has long\u2010lasting effects on vascular endothelial growth factor receptor phosphorylation and function","volume":"6","author":"Mendel DB","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.12.883"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc778"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0434"},{"key":"e_1_2_6_39_2","first-page":"39","article-title":"Vascular endothelial growth factor receptor\u20102\u2010blocking antibody potentiates radiation\u2010induced long\u2010term control of human tumor xenografts","volume":"61","author":"Kozin SV","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_40_2","first-page":"5565","article-title":"Anti\u2010vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions","volume":"60","author":"Lee CG","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_6_41_2","first-page":"191","article-title":"Antibody\u2010based targeting of angiogenesis","volume":"16","author":"Halin C","year":"2001","journal-title":"News Physiol Sci"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.neo.7900006"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2004.03.001"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020072"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-0271fje"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5415.808"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0361-090X(03)00030-8"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203969"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.4.287"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006317125454"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00279-8"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.21838","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.21838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T20:24:29Z","timestamp":1695932669000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.21838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,27]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,7,15]]}},"alternative-id":["10.1002\/ijc.21838"],"URL":"https:\/\/doi.org\/10.1002\/ijc.21838","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,27]]}}}